Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. (April 2011)

• Record Type: Journal Article
• Authors: Lasker, George F; Maley, Jason H; Pankey, Edward A; Kadowitz, Philip J
• Is Part Of: Expert review of respiratory medicine. Volume 5:Number 2(2010)
• Page Start: 153
• Page End: 161
• Publication Date: 2011-04
• Subjects: activators -- endothelial dysfunction -- nitric oxide -- pulmonary hypertension -- soluble guanylate cyclase -- stimulators; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1586/ers.11.9
• Languages: English
• ISSNs: 1747-6348

Abstract

Pulmonary arterial hypertension is a disease characterized by a sustained increase in pulmonary arterial pressure leading to right heart failure. Current treatments focus on endothelial dysfunction and an aberrant regulatory pathway for vascular tone. Unfortunately, a large proportion of patients are unresponsive to conventional vasodilator therapy. Investigations are ongoing into the effects of experimental therapies targeting the signal transduction pathway that mediates vasodilation. Here, we briefly discuss the pathophysiology of pulmonary hypertension and endothelial dysfunction, along with current treatments. We then present a focused review of recent animal studies and human trials examining the use of activators and stimulators of soluble guanylate cyclase for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.